Top Premarket Decliners
Why BloomZ Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Buy Rating on Mersana Therapeutics: Anticipated Upside From XMT-1660 Development and Market Valuation Disconnect
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Announces Target Price $9
Mersana Therapeutics Is Maintained at Buy by Citigroup
Citi Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $5
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Chimerix (CMRX) and Mersana Therapeutics (MRSN)
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Analysts Are More Bearish Than They Used To Be
Express News | Baird Maintains Neutral on Mersana Therapeutics, Lowers Price Target to $3
Mersana Therapeutics Analyst Ratings
BTIG Initiates Mersana Therapeutics(MRSN.US) With Buy Rating, Announces Target Price $6
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
Truist Financial Issues a Buy Rating on Mersana Therapeutics (MRSN)
Buy Rating on Mersana Therapeutics: Advancing XMT-1660 Program and Promising Tolerability Profile
Express News | Mersana Therapeutics Inc : Baird Cuts Target Price to $3 From $4
TD Cowen Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
Earnings Call Summary | Mersana Therapeutics(MRSN.US) Q2 2024 Earnings Conference
Mersana Therapeutics | 10-Q: Q2 2024 Earnings Report